Mrs Susan Hawkey, Healthcare Communications Specialist, Birmingham

New incentives for government support for antibiotic development is critical. Pharmaceutical companies have limited reserves for R&D and there are many blocks to fast and efficient R&D in the EU. The process needs simplification and how can government future development when the financial gains for the industry are limited by time and resistance issues.